20.01.2013 Views

Pharmaceuticals Sector - Solvay

Pharmaceuticals Sector - Solvay

Pharmaceuticals Sector - Solvay

SHOW MORE
SHOW LESS

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

62<br />

<strong>Solvay</strong> Global Annual Report 2005<br />

5. Retirement benefi t costs<br />

The Group operates a number of defi ned benefi t and<br />

defi ned contribution retirement benefi t plans. Payments<br />

to defi ned contribution retirement benefi t plans are<br />

charged as an expense as they fall due.<br />

The Group’s commitments under defi ned benefi ts<br />

plans, and the related costs, are valued using the<br />

“projected unit credit method” in order to determine<br />

the present value of the obligation at closing date.<br />

The amount recorded in the balance sheet represents<br />

the present value of the defi ned benefi t obligations,<br />

adjusted for actuarial differences, for unrecognized<br />

past services costs and for the fair value of external<br />

plan assets, limited in the case of a surplus to the<br />

present value of available refunds and/or reductions in<br />

future contributions.<br />

Actuarial differences exceeding the higher of 10% of<br />

the present value of the retirement benefi t obligations<br />

and 10% of the fair value of the assets of the<br />

external plan assets at balance sheet closing date<br />

are amortized over the expected average remaining<br />

working life of the participating employees.<br />

6. Income taxes<br />

Income taxes on profi ts for the period include both<br />

current and deferred taxes. They are recorded in the<br />

income statement except where they relate to items<br />

recorded directly in equity, in which case they too are<br />

recorded in equity.<br />

Current taxes are taxes payable on the taxable profi t<br />

for the period, calculated at the tax rates prevailing at<br />

the balance sheet closing date, as well as adjustments<br />

relating to previous periods.<br />

Deferred tax assets and liabilities are required to be<br />

measured at the tax rates that are expected to apply<br />

to the fi nancial year in which the asset is realized or the<br />

liability is settled, based on tax rates (and tax laws) that<br />

have been enacted or substantively enacted by the<br />

balance sheet date.<br />

Deferred tax liabilities relating to subsidiaries’ profi ts<br />

that the Group does not intend distributing in the<br />

foreseeable future are not accounted for.<br />

Deferred tax assets are recognized only where taxable<br />

profi ts are likely to be realized, against which the<br />

deferred tax assets will be imputed.<br />

7. Tangible and intangible assets<br />

Tangible and intangible assets are carried at their<br />

historical cost less depreciation/amortization.<br />

Depreciation/amortization is included in the income<br />

statement under cost of goods sold, commercial and<br />

administrative costs, and in R&D costs.<br />

Depreciation/amortization is calculated on a straightline<br />

basis, according to the useful life listed below:<br />

Buildings 30 years<br />

IT equipment 3 - 5 years<br />

Machinery and equipment 10 - 20 years<br />

Transportation equipment 5 - 20 years<br />

Patents and trademarks 5 - 20 years<br />

Assets held under fi nance leases are initially recognized<br />

as assets at the lower of their fair value or the present<br />

value of the minimum lease payments related to the<br />

contracts. The corresponding liability is included<br />

in fi nancial debts. Financial charges, representing<br />

the difference between the full amount of the lease<br />

obligations and the fair value of the assets acquired,<br />

are charged to the income statement over the duration<br />

of the contract.<br />

Borrowing costs directly attributable to the acquisition,<br />

construction or production of an asset requiring a long<br />

preparation period are added to the cost of this asset<br />

until it is ready for use.<br />

Grants for the purchase of assets are recorded net of<br />

the value of these assets.<br />

8. Research and Development costs<br />

Research costs are charged in the period in which they<br />

are incurred.<br />

Development costs are capitalized if, and only if all the<br />

following conditions are fulfi lled:<br />

- the product or process is clearly defi ned and the<br />

related costs are measured reliably and can be<br />

separately identifi ed;<br />

- the technical feasibility of the product has been<br />

demonstrated;<br />

- the product or process will be placed on the market<br />

or used internally;<br />

- the assets will generate future economic benefi ts (a<br />

potential market exists for the product or, where it is<br />

to be used internally, its future utility is demonstrated);<br />

- the technical, fi nancial and other resources required<br />

to complete the project are available.<br />

The capitalized development costs are amortized on<br />

a straight-line basis over their useful lives.<br />

- the technical, fi nancial and other resources required<br />

to complete the project are available.<br />

The capitalized development costs are amortized on a<br />

straight-line basis over their useful lives.

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!